Wednesday, April 6, 2016

7:00–8:00 am Registration, Breakfast, Visit Exhibitors
8:00–8:15 Opening Remarks
Patrycja Dubielecka-Szczerba, PhD and John L. Reagan, MD
8:15–8:45 Non-engraftment Donor Lymphocyte Infusions for Refractory Acute Myeloid Leukemia
John L. Reagan, MD
Optimizing Anti-Leukemic Responses Induced by Patient Alloreactive Responses
Loren D. Fast, MD
9:15–9:45 The Role of Microtransplantation as Frontline Therapy for Acute Myeloid Leukemia
Anthony D. Sung, MD
9:45–10:15 Break and Visit Exhibitors
10:15–10:45 Haploidentical Stem Cell Transplantation for Myeloid Malignancies: Past, Present & Future
Thomas R. Spitzer, MD
10:45–11:15 Novel Ways to Activate NK Cells to Treat Cancer
Jeffrey Miller, MD
11:15–11:45 A Hypothesis For the Mechanism of the Anti-tumor Effect of Non-Engrafting Donor Lymphocyte Infusions
Ephraim J. Fuchs, MD
11:45-12:45 pm Lunch and Visit Exhibitors
12:45–1:15 Neuro-Endocrine Regulation of the Hematopoietic Stem Cell Niche
Paul S. Frenette, MD
1:15–1:45 Presentation Title TBC
Dorothy A. Sipkins, MD, PhD
1:45–2:15 Beta 1 Integrins in Hematopoietic Stem/Progenitor Trafficking and in Erythropoiesis
Thalia Papayannopoulu, MD
2:15–2:45 Break and Visit Exhibitors
2:45–3:15 BET Protein Bromodomain Inhibitor-Based Therapy of Acute Myeloid Leukemia
Kapil N. Bhalla, MD
3:15–3:45 Development of Novel Therapeutics for Megakaryocytic Malignancies
John D. Crispino, PhD
3:45–4:15 New Signaling Mechanismin Myelofibrosis
Patrycja Dubielecka-Szczerba, PhD
4:15–4:45 pm Novel Therapies for Myelodysplastic Syndrome
David P. Steensma, MD